Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

SUBLOKADE Langsigtede resultater

3. november 2026 opdateret af: Indivior Inc.

Et fase IV longitudinelt studie af SUBLOCADE (SUBUTEX forlænget frigivelse) kliniske resultater hos voksne med opioidbrugsforstyrrelse (opioidafhængighed)

This study will provide the opportunity to generate data on the long-term use of SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle, health, and sociodemographic factors that are part of the recovery process. Long-term patterns of abstinence/opioid misuse as well as measures of participants' physical, psychological, social, and economic well-being will be monitored to better understand factors associated with recovery from opioid use disorder (OUD). Therefore, this study will observe participants up to a maximum of 4 years.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

This is a Phase IV, prospective, multicentre, multinational, open-label, real-world observational study in participants with current or a history of OUD/opioid dependence.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

480

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Richmond, Australien, VIC 3121
        • Turning Point
    • Melbourne
      • Fitzroy, Melbourne, Australien, 3065
        • St Vincent's Hospital Melbourne
    • New South Wales
      • Newcastle, New South Wales, Australien, 2300
        • John Hunter Hospital
    • South Australia
      • Stepney, South Australia, Australien, 5069
        • Drug and Alcohol Services South Australia (DASSA)
    • Alberta
      • Calgary, Alberta, Canada, T2E2R2
        • Smart Clinic
      • Edmonton, Alberta, Canada, T5J 3E4
        • Recovery Alberta
    • British Columbia
      • Surrey, British Columbia, Canada, V3T 0H1
        • Fraser Health Authority
    • Ontario
      • Burlington, Ontario, Canada, L7M 4X9
        • Dr. J.S. Dhillon Medicine Prof. Corp
      • Hamilton, Ontario, Canada, L8N 1H3
        • The Stipley Clinic
      • Owen Sound, Ontario, Canada, N4K 6M9
        • Brightshores Health System
      • Sarnia, Ontario, Canada, N7T 5W9
        • Bluewater Rapid Assessment Addiction Medicine Clinic
      • Toronto, Ontario, Canada, M4J 1M3
        • Comprehensive Treatment Clinic
    • California
      • Costa Mesa, California, Forenede Stater, 92626
        • ATP Clinical Research
      • Escondido, California, Forenede Stater, 92025
        • Neighborhood Healthcare-Institute of Health
    • Connecticut
      • Westport, Connecticut, Forenede Stater, 06880
        • Elevate Health and Wellness
    • Florida
      • Hialeah, Florida, Forenede Stater, 33012
        • United Research Institute
      • Hollywood, Florida, Forenede Stater, 33021
        • Zenith Clinical Research LLC
      • Miami, Florida, Forenede Stater, 33126
        • Jackson Health Community Center
      • Miami, Florida, Forenede Stater, 33134
        • G+C Research Group
    • Georgia
      • Decatur, Georgia, Forenede Stater, 30033-4004
        • Atlanta VA Medical Center
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66160
        • University of Kansas Medical Center
      • Prairie Village, Kansas, Forenede Stater, 66210
        • Collective Medical Research.
    • Maine
      • Scarborough, Maine, Forenede Stater, 04074-7163
        • Maine Health
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21229
        • Maryland Treatment Centers
    • Massachusetts
      • Springfield, Massachusetts, Forenede Stater, 01199
        • Baystate Health
    • Michigan
      • Dearborn, Michigan, Forenede Stater, 48124
        • THRYV Clinical Studies
      • Dearborn Heights, Michigan, Forenede Stater, 48127
        • Vida Clinical Studies
      • Detroit, Michigan, Forenede Stater, 48201
        • Wayne State University Hospital
      • Fair Haven, Michigan, Forenede Stater, 48023
        • North Point Medical Center
      • Grand Rapids, Michigan, Forenede Stater, 49503-4224
        • SHMG Center for Integrative Medicine
    • Mississippi
      • Tupelo, Mississippi, Forenede Stater, 38801
        • North Mississippi Medical Center
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63141-8704
        • Psych Care Consultants
    • New York
      • Amherst, New York, Forenede Stater, 14226
        • DENT Neurologic Institute
      • Binghamton, New York, Forenede Stater, 13903
        • United Health Services
      • New York, New York, Forenede Stater, 10029
        • Icahn School of Medicine at Mount Sinai
      • North New Hyde Park, New York, Forenede Stater, 11042
        • Core Clinical Trials
      • Rockville Centre, New York, Forenede Stater, 11570
        • Stuart Wasser Practice
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28277
        • Onsite Clinical Solutions LLC
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73112
        • Pahl Pharmaceutical Professionals LLC
    • Oregon
      • Corvallis, Oregon, Forenede Stater, 97330
        • Healing Comfort Clinic, LLC
    • Pennsylvania
      • Narberth, Pennsylvania, Forenede Stater, 19072
        • Thalia Medical Centre
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29407
        • Charleston Pain and Rehabilitation Center
      • Columbia, South Carolina, Forenede Stater, 29205
        • Midlands Neurology
      • Greenville, South Carolina, Forenede Stater, 29605
        • Prisma Health
    • Texas
      • Houston, Texas, Forenede Stater, 77043
        • Biopharma Informatic, Inc. Research Center
    • Utah
      • Clinton, Utah, Forenede Stater, 84015
        • Alpine Research Organization
    • Virginia
      • Richmond, Virginia, Forenede Stater, 23219
        • Virginia Commonwealth University
      • Linköping, Sverige, 58185
        • Linkoping University Hospital, Psychiatry Center
      • Stockholm, Sverige, SE-11365
        • Beroendecentrum

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Participants may enroll if they have initiated treatment with SUBLOCADE within 3 months prior to signing the informed consent form (ICF), or have completed an Indivior SUBLOCADE study (eg, INDV-6000-401, INDV-6000-405) and received their last dose of SUBLOCADE on the study within 3 months prior to signing the ICF, and plan to receive additional SUBLOCADE injections.

Beskrivelse

Inclusion Criteria:

Participants must meet all of the following criteria:

  • Is an adult ≥ 18 years of age who has signed the informed consent form

  • Plans to receive additional SUBLOCADE injections and

    • Has initiated treatment for OUD/opioid dependence with SUBLOCADE within the last 3 months prior to Baseline Visit

      • OR
    • Has completed an Indivior SUBLOCADE study (eg, INDV-6000-401, INDV-6000-405) and has received the last dose of SUBLOCADE on that study within 3 months prior to Baseline Visit

  • Is not currently participating in any clinical trial requiring medical intervention

  • Is not currently using opioids to treat a diagnosis other than OUD/opioid dependence

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Participants achieving DSM-5 remission, early or sustained, (yes/no) while on initial SUBLOCADE treatment by 6 months and 1, 1.5, 2, 2.5, and 3 years from study Baseline
Tidsramme: up to a maximum of 4 years
  • Definition of early remission: None of the criteria for OUD has been met for at least 3 months but for less than 12 months with the exception that Criterion 4 ("Craving, or a strong desire or urge to use opioids,") may be met.
  • Definition of sustained remission: None of the criteria for OUD has been met for at least 12 months with the exception that Criterion 4 ("Craving, or a strong desire or urge to use opioids,") may be met.
up to a maximum of 4 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Key Secondary: Participants with "no symptoms" or improving by ≥1 DSM-5 severity classification within the last 3 months (moderate to mild, or severe to mild or moderate) relative to study Baseline (yes/no) at Month 6 and Years 1, 2, and 3
Tidsramme: up to a maximum of 4 years

DSM-5-Related

up to a maximum of 4 years
Among those starting SUBLOCADE within 3 months of study Baseline, time to achieve early remission for the first time while on initial SUBLOCADE treatment
Tidsramme: up to a maximum of 4 years

DSM-5-Related

up to a maximum of 4 years
Participants achieving DSM-5 sustained remission (yes/no) by 1, 1.5, 2, 2.5, and 3 years while on initial SUBLOCADE treatment
Tidsramme: up to a maximum of 4 years

DSM-5-Related

up to a maximum of 4 years
Time to achieve sustained remission for the first time while on initial SUBLOCADE treatment
Tidsramme: up to a maximum of 4 years

DSM-5-Related

up to a maximum of 4 years
Time to discontinuing initial SUBLOCADE treatment and the corresponding reasons for discontinuation, eg, resolution of OUD symptoms, safety concerns, treatment failure, or seeking alternative MOUD treatment
Tidsramme: up to a maximum of 4 years

MOUD Use and Retention

up to a maximum of 4 years
Participants switching from initial SUBLOCADE treatment to another MOUD (yes/no), and the corresponding reasons, eg, safety concerns, treatment failure, seeking alternative MOUD treatment
Tidsramme: up to a maximum of 4 years

MOUD Use and Retention

up to a maximum of 4 years
The overall treatment duration for participants who stop initial SUBLOCADE treatment as the result of resolution of OUD symptoms
Tidsramme: up to a maximum of 4 years

MOUD Use and Retention

up to a maximum of 4 years
Participants with any positive opioid use in the past month (yes/no) at Month 6 and Years 1, 2, and 3 while on initial SUBLOCADE treatment
Tidsramme: up to a maximum of 4 years

Illicit Opioid Use (Self-Reports)

up to a maximum of 4 years
Participants with opioid overdose requiring intervention (yes/no) while on initial SUBLOCADE treatment at least once during the first 6 months, and during Years 1, 2, and 3
Tidsramme: up to a maximum of 4 years

Opioid Overdose Requiring Intervention

up to a maximum of 4 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

31. august 2023

Primær færdiggørelse (Faktiske)

31. august 2025

Studieafslutning (Faktiske)

31. august 2025

Datoer for studieregistrering

Først indsendt

5. maj 2023

Først indsendt, der opfyldte QC-kriterier

5. maj 2023

Først opslået (Faktiske)

16. maj 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • INDV-6000-406

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .